Literature DB >> 16387425

MRP2 and 3 in health and disease.

P Borst1, N Zelcer, K van de Wetering.   

Abstract

MRPs are membrane proteins transporting organic anions at the expense of ATP hydrolysis. MRP2 is known to be a major transporter of organic anions from the liver into bile. We discuss recent results showing allosteric control of human but not rat MRP2. MRP3 has been considered a major player in bile salt metabolism, but our recent results with Mrp3 KO mice do not support this. Instead, we have found a role for MRP3 in the cellular export of drug-glucuronide conjugates. We discuss problems in extrapolating results obtained for murine MRPs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16387425     DOI: 10.1016/j.canlet.2005.05.051

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  24 in total

1.  Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome.

Authors:  Motofumi Tanaka; Taro Okazaki; Hideo Suzuki; James L Abbruzzese; Donghui Li
Journal:  Cancer       Date:  2010-10-04       Impact factor: 6.860

2.  A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration.

Authors:  Gromoslaw A Smolen; Jianmin Zhang; Matthew J Zubrowski; Elena J Edelman; Biao Luo; Min Yu; Lydia W Ng; Cally M Scherber; Benjamin J Schott; Sridhar Ramaswamy; Daniel Irimia; David E Root; Daniel A Haber
Journal:  Genes Dev       Date:  2010-11-09       Impact factor: 11.361

Review 3.  Transporters in the intestine limiting drug and toxin absorption.

Authors:  R P J Oude Elferink; R de Waart
Journal:  J Physiol Biochem       Date:  2007-03       Impact factor: 4.158

4.  CFTR-associated ligand is a negative regulator of Mrp2 expression.

Authors:  Man Li; Carol J Soroka; Kathy Harry; James L Boyer
Journal:  Am J Physiol Cell Physiol       Date:  2016-11-09       Impact factor: 4.249

5.  Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.

Authors:  Sarah J Schrieber; Roy L Hawke; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Catherine M Meyers; Edward Doo; Michael W Fried
Journal:  Drug Metab Dispos       Date:  2011-08-24       Impact factor: 3.922

Review 6.  Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases.

Authors:  Zhe-Sheng Chen; Amit K Tiwari
Journal:  FEBS J       Date:  2011-08-01       Impact factor: 5.542

Review 7.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

Review 8.  Gene replacement therapy for genetic hepatocellular jaundice.

Authors:  Remco van Dijk; Ulrich Beuers; Piter J Bosma
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

9.  Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs.

Authors:  Pär Matsson; Jenny M Pedersen; Ulf Norinder; Christel A S Bergström; Per Artursson
Journal:  Pharm Res       Date:  2009-05-07       Impact factor: 4.200

10.  Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump.

Authors:  Yvonne Meier; Tina Zodan; Carmen Lang; Roland Zimmermann; Gerd A Kullak-Ublick; Peter J Meier; Bruno Stieger; Christiane Pauli-Magnus
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.